Concepedia

Pilar Nava-Parada

PN

6

Publications

294

Citations

6

H-Index

2007

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Pilar Nava-Parada is an author at The University of Texas MD Anderson Cancer Center specializing in tumor immunology, cell transplantation, and peptide therapeutics.

ORCID

Top concepts

Publications per year

2007–2023

6

Publications

6

Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast Tumors

Pilar Nava-Parada, Guido Forni, Keith L. Knutson et al. · Cancer Research · 2007 · 102 citations · Full text

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Robin L. Jones, Edward S. Kim, Pilar Nava-Parada et al. · Clinical Cancer Research · 2014 · 93 citations

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, Wael A. Harb, Brian T. Hill et al. · Blood · 2013 · 45 citations

GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers.

Pilar Nava-Parada, Leisha A. Emens · PubMed · 2007 · 28 citations

, , +17

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar

Jocelyn Courville, Loretta J. Nastoupil, Nitin Kaila et al. · BioDrugs · 2021 · 16 citations · Full text

Rows per page

1–5 of 6